Teladoc Health

teladochealth.com

Teladoc Health is the global virtual care leader, offering the only comprehensive virtual care solution spanning telehealth, expert medical, and licensed platform services. Through our award-winning consumer experience brands – Advance Medical, Best Doctors, BetterHelp, HealthiestYou, and Teladoc – we help millions of people around the world resolve their healthcare needs with confidence.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

DEBIOPHARM ANNOUNCES FIRST PATIENT DOSED IN INVESTIGATOR-INITIATED, RANDOMIZED PHASE II, OPEN-LABEL CLINICAL TRIAL FOR ITS ANTIVIRAL ALISPORIVIR

Debiopharm | January 18, 2021

news image

Debiopharm , a Swiss biopharmaceutical organization, reported the principal patient dosed in a investigator-initiated, randomized phase II, open-label clinical trial for its antiviral alisporivir (Debio 025). The examination will be led by the AP-HP to assess the adequacy and wellbeing of the cyclophilin inhibitor in the therapy of beginning phase, hospitalized COVID-19 patients who don't need clinical ventilation and have not shown indications of intense respiratory distress syndrome. The e...

Read More

Cell and Gene Therapy, AI

BENEVOLENTAI PROGRESSES BEN-34712 FOR THE POTENTIAL TREATMENT OF ALS INTO IND-ENABLING STUDIES

Businesswire | June 05, 2023

news image

BenevolentAI, a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712. BEN-34712 is an oral, potent and selective brain penetrant RARɑβ (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies. Impaired retinoic acid signalling has bee...

Read More

Industrial Impact

ADAPTIVE BIOTECHNOLOGIES ANNOUNCES NEW DATA DEMONSTRATING IMMUNOSEQ® TECHNOLOGY CAN IDENTIFY T-CELL RECEPTORS ASSOCIATED WITH CROHN’S DISEASE

Adaptive Biotechnologies | February 19, 2022

news image

Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, presented data on T-cell receptor (TCR) sequences associated with Crohn’s disease (CD) during an oral presentation today at the 17th Congress of European Crohn’s and Colitis Organisation (ECCO) being held virtually February 16-19. The study identified and characterized TCR sequences associ...

Read More

Medical

RIDGEBACK BIOTHERAPEUTICS LP ANNOUNCES THE U.S. FOOD AND DRUG ADMINISTRATION APPROVEL OF EBANGATM FOR EBOLA

Ebanga | December 29, 2020

news image

Ridgeback Biotherapeutics LP ("Ridgeback"), a biotechnology organization experienced in antiviral drug improvement, reported today that the U.S. Food and Drug Administration ("FDA") approved EbangaTM for the treatment of Ebola. Ebanga is presently affirmed for treatment of disease brought about by Zaire ebolavirus in grown-up and pediatric patients. Ebanga is the only FDA endorsed, single infusion Ebola treatment which is accessible in a lyophilized structure.<...

Read More
news image

Medical

DEBIOPHARM ANNOUNCES FIRST PATIENT DOSED IN INVESTIGATOR-INITIATED, RANDOMIZED PHASE II, OPEN-LABEL CLINICAL TRIAL FOR ITS ANTIVIRAL ALISPORIVIR

Debiopharm | January 18, 2021

Debiopharm , a Swiss biopharmaceutical organization, reported the principal patient dosed in a investigator-initiated, randomized phase II, open-label clinical trial for its antiviral alisporivir (Debio 025). The examination will be led by the AP-HP to assess the adequacy and wellbeing of the cyclophilin inhibitor in the therapy of beginning phase, hospitalized COVID-19 patients who don't need clinical ventilation and have not shown indications of intense respiratory distress syndrome. The e...

Read More
news image

Cell and Gene Therapy, AI

BENEVOLENTAI PROGRESSES BEN-34712 FOR THE POTENTIAL TREATMENT OF ALS INTO IND-ENABLING STUDIES

Businesswire | June 05, 2023

BenevolentAI, a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712. BEN-34712 is an oral, potent and selective brain penetrant RARɑβ (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies. Impaired retinoic acid signalling has bee...

Read More
news image

Industrial Impact

ADAPTIVE BIOTECHNOLOGIES ANNOUNCES NEW DATA DEMONSTRATING IMMUNOSEQ® TECHNOLOGY CAN IDENTIFY T-CELL RECEPTORS ASSOCIATED WITH CROHN’S DISEASE

Adaptive Biotechnologies | February 19, 2022

Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, presented data on T-cell receptor (TCR) sequences associated with Crohn’s disease (CD) during an oral presentation today at the 17th Congress of European Crohn’s and Colitis Organisation (ECCO) being held virtually February 16-19. The study identified and characterized TCR sequences associ...

Read More
news image

Medical

RIDGEBACK BIOTHERAPEUTICS LP ANNOUNCES THE U.S. FOOD AND DRUG ADMINISTRATION APPROVEL OF EBANGATM FOR EBOLA

Ebanga | December 29, 2020

Ridgeback Biotherapeutics LP ("Ridgeback"), a biotechnology organization experienced in antiviral drug improvement, reported today that the U.S. Food and Drug Administration ("FDA") approved EbangaTM for the treatment of Ebola. Ebanga is presently affirmed for treatment of disease brought about by Zaire ebolavirus in grown-up and pediatric patients. Ebanga is the only FDA endorsed, single infusion Ebola treatment which is accessible in a lyophilized structure.<...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us